GAITHERSBURG, Md. -- (BUSINESS WIRE) -- MaxCyte, Inc., the pioneer in scalable, high performance transient transfection systems, is hosting an educational webinar entitled Transient Transfection of Biologically Relevant Cells: CEVEC CAP-T™ Technology for High Yield Expression of Proteins in Human Derived Cells on Wednesday, December 12, 2012, from 11:00 AM – 12:00 PM EST. This scientific program will focus on the use of MaxCyte’s proprietary large scale transfection platform in combination with Cevec’s CAP-T technology for the production of proteins and antibodies with authentic human glycosylation and sialylation. Technical presentations will be given by Dr. James Brady, Director of Technical Applications at MaxCyte, and Dr. Hartmut Tintrup, VP Business Development & Licensing at Cevec Pharmaceuticals.
“Post translational modifications of proteins and antibodies can have significant impacts on their efficacy as therapeutics. MaxCyte-enabled transfection of Cevec’s CAP-T cells allows companies to rapidly generate proteins with authentic human glycosylation and sialylation in sufficient quantities for characterization early in development, which greatly improves the quality of their candidate selection process,” says Dr. Tintrup of Cevec. Data within the webinar will demonstrate the use of the MaxCyte STX® Scalable Transfection System to transiently transfect CAP-T cells with high efficiency enabling rapid production of antibodies with human post translational modifications at titers greater than 600mg/L.
“The biopharmaceutical industry has expressed tremendous interest in using the MaxCyte transient transfection platform for protein production and biotherapeutic development,” says Douglas Doerfler, CEO and President of MaxCyte. “MaxCyte offers two systems in its scalable transfection platform: the MaxCyte STX® Scalable Transfection System for transfection of up to 1E10 cells and the MaxCyte VLX® Large Scale Transfection System for transfection of up to 2E11 cells. Both systems in the MaxCyte platform achieve these large scale transfections in a single 20-30 minute run to produce gram to multi-gram level quantities of antibodies and proteins in relevant cells such as CHO and CAP-T from the earliest stages of development.”
Interested participants can register for the webinar on MaxCyte’s web site www.maxcyte.com/MaxCyte-Company/MaxCyte-Upcoming-Webinar.html, to learn how MaxCyte Scalable Transfection Systems can accelerate biotherapeutic development pipelines using large scale, transient transfection of CAP-T, CHO, and other biologically relevant cells.
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte has designed a portfolio of products including the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System, ideal tools for use in drug discovery research, screening, and protein production environments. These products enable the rapid development and consistent production of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production and for cell‐based assays, with comparable results and Seamless Scalability™ from the bench to HTS and biomanufacturing scale.
About CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins, vaccines, and monoclonal antibodies with human glycosylation patterns. CEVEC's novel proprietary and patent-protected human CAP® and CAP-TTM expression systems are ideal for manufacturing complex biopharmaceutical molecules and various vaccines. CEVEC is licensing out its human cell-based expression platform as well as its own biobetter candidates through partnerships with renowned pharmaceutical and biotech companies.